TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23458405
Drug: CoQ10 supplementation
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 supplementation (300 mg/day for 40 days)
Study: 30814417
Drug: Curcumin ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin ingestion (180 mg/d) 4 d after exercise (POST)
Study: 30814417
Drug: Curcumin ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin ingestion (180 mg/d) 7 d before exercise (PRE)
Study: 30814417
Drug: Placebo (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (180 mg/d) 4 d after exercise (CON)
Study: 21205939
Drug: Intraarterial administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarterial administration of BM‐MNC
Study: 21205939
Drug: Repeated BM‐MNC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated BM‐MNC administration
Study: 21205939
Drug: Ulcer healing
Normalized name: Ulcer healing agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulcer healing induced by repeated BM‐MNC administration
Study: 15327525
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose coumadin (1 mg/d)
Study: 15327525
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH, enoxaparin 40 mg s.c. q.d.)
Study: 15327525
Drug: Thalidomide and
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide and chemotherapy during consolidation treatment
Study: 9052314
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg cisatracurium
Study: 9052314
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg cisatracurium
Study: 2576216
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg vecuronium
Study: 8134772
Drug: Five doses
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five doses of ivermectin
Study: 8134772
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ivermectin
Study: 3526522
Drug: TL-102 (beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: TL-102 (beclomethasone dipropionate powder preparation) 50 micrograms with 30 micrograms of hydroxypropylcellulose, administered intranasally at a dose of 2 capsules/day b.i.d. for one week
Study: 3526522
Drug: TL-102 (beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: TL-102 (beclomethasone dipropionate powder preparation)
Study: 3526522
Drug: Conventional BDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional BDP preparations
Study: 27055601
Drug: Relamorelin 10
Normalized name: Relamorelin
DrugBank: Relamorelin (DB12678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relamorelin 10 μg twice daily
Study: 25027701
Drug: Thiamin supplementation
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamin supplementation (10 mg/day for 7 days, then 5 mg daily until day 42)
Study: 20187947
Drug: Early medication
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early medication change (EMC) strategy
Study: 16307968
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (Leuprorelin 3.75 mg/28 days)
Study: 16307968
Drug: Subdermal progestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subdermal progestin implant (etonogestrel 68 mg)
Study: 10714913
Drug: Calcium alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium alone (750 mg)
Study: 11193131
Drug: CEE 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.3 mg
Study: 11591613
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg
Study: 26405233
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of autologous bone marrow-derived cells (BMC)
Study: 25350669
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 50,000 IU once a week for 2 months and then monthly for 10 months
Study: 22406101
Drug: Supportive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive Therapy (Control)
Study: 7959187
Drug: Gelatin capsules
Normalized name: Gelatin Capsules
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsules
Study: 18794541
Drug: Chemotherapy (CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT arm; fluorouracil [FU] 400 mg/m(2) IV once daily plus dl‐leucovorin 200 mg/m(2) for 5 days or FU 370 mg/m(2) plus l‐leucovorin 100 mg/m(2) IV for 5 days for six cycles at 28-day intervals)
Study: 18794541
Drug: Chemotherapy (CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT arm)
Study: 9683312
Drug: Controlled onset-extended
Normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Oncet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled onset-extended release (COER)-verapamil (180 mg/d)
Study: 7655108
Drug: Calcipotriol in
Normalized name: Product containing calcipotriol in cutaneous dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol in ointment for 12 weeks
Study: 7655108
Drug: Ointment base
Normalized name: Ointment base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment base only for 12 weeks
Study: 30341006
Drug: Cligosiban 0.3-2,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cligosiban 0.3-2,400 mg (aqueous solutions or dispersions)
Study: 30341006
Drug: Cligosiban 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cligosiban 800 mg (capsules and aqueous dispersion)
Study: 30341006
Drug: Cligosiban 1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cligosiban 1,600 mg (caplets and aqueous dispersion)
Study: 30341006
Drug: Cligosiban (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cligosiban (various doses)
Study: 30341006
Drug: Cligosiban (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cligosiban (800 mg)
Study: 19455053
Drug: High-dose CP-532,623
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CP-532,623
Study: 19455053
Drug: Low-dose CP-532,623
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose CP-532,623
Study: 11379808
Drug: HFA-BDP (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA-BDP (200 to 800 microg daily)
Study: 11379808
Drug: CFC-BDP (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFC-BDP (400 to 1600 microg daily)
Study: 11072419
Drug: Caffeine 400
Normalized name: caffeine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 400 mg
Study: 3222359
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg and 400 mg)
Study: 27051055
Drug: Interval cytoreductive
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval cytoreductive surgery (CS) with hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin (50 mg/m2) for 60 minutes after complete cytoreduction.
Study: 27051055
Drug: Standard first-line
Normalized name: Standard ANSI First Aid KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard first-line treatment (6 conventional cycles of chemotherapy after CS with HIPEC).
Study: 22614720
Drug: Decaffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated coffee with 67 mg caffeine
Study: 22614720
Drug: Decaffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated coffee with 134 mg caffeine
Study: 21879101
Drug: Regular coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular coffee (130 mg caffeine)
Study: 21879101
Drug: Placebo-control capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-control capsule
Study: 15025848
Drug: Liquid formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation of r-hCG (0.5 mL of 250 microg/0.5 mL)
Study: 15025848
Drug: Freeze-dried formulation
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-dried formulation of r-hCG (1.0 mL of 250 microg/mL)
Study: 10990077
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin (5 mg daily)
Study: 3966831
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K treatment
Study: 27783849
Drug: Peptide cocktail
Normalized name: Multipeptide cocktail
DrugBank: CoVac-1 (DB16429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide cocktail therapy (KIF20A-derived peptide vaccine combined with antiangiogenic cancer vaccines targeting VEGFR1 and VEGFR2) plus gemcitabine
Study: 12899793
Drug: rhIFN-gamma (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIFN-gamma (1 MU intramuscularly daily for the first three months and 1 MU every other day for the following six months)
Study: 12730746
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg risedronate
Study: 12633783
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg risedronate
Study: 10709154
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg risedronate
Study: 30953319
Drug: GLPG1690 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG1690 600 mg once daily for 12 weeks
Study: 30953319
Drug: GLPG1690 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG1690 (various doses from 20 mg to 1500 mg, including multiple daily doses of 300-1000 mg)
Study: 31179008
Drug: GLPG1690 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG1690 600 mg
Study: 27050139
Drug: Intra-articular sprifermin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular sprifermin (300 μg)
Study: 27050139
Drug: Intra-articular sprifermin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular sprifermin (single and multiple doses)
Study: 25048494
Drug: Once-daily tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily tacrolimus (extended-release), converted from twice-daily tacrolimus at 1 month post-transplantation
Study: 26360125
Drug: Twice-daily tacrolimus
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily tacrolimus
Study: 31993943
Drug: Once-daily tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily tacrolimus
Study: 22508830
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg plus entinostat 10 mg (EE)
Study: 22508830
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg plus placebo (EP)
Study: 20181970
Drug: Lasofoxifene 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasofoxifene 0.5 mg/day
Study: 20181970
Drug: Lasofoxifene 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasofoxifene 0.25 mg/day
Study: 15643700
Drug: DTP-PRP-T (Hib
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP-PRP-T (Hib conjugate) vaccine
Study: 11115824
Drug: Lexipafant (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lexipafant (100 mg/24 hours intravenously for seven days)
Study: 9531201
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (suture repair of disrupted ligaments within 72 hours, followed by immobilization in a below-the-knee plaster cast for 6 weeks)
Study: 9531201
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment (ankle orthosis for 6 weeks)
Study: 8010422
Drug: Dorsal penile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsal penile nerve block (DPNB) with additional ventral injection
Study: 2499490
Drug: Endobronchial glypressin
Normalized name: Lypressin
DrugBank: Lypressin (DB14642)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endobronchial glypressin (1 mg)
Study: 2499490
Drug: Intravenous glypressin
Normalized name: Lypressin
DrugBank: Lypressin (DB14642)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous glypressin (1 mg)
Study: 2499490
Drug: Intravenous glypressin
Normalized name: Lypressin
DrugBank: Lypressin (DB14642)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous glypressin
Study: 31738448
Drug: Lidocaine 0.5%
Normalized name: LIDOCAINE 0.5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 0.5% (5 mL)
Study: 31738448
Drug: Lidocaine 0.5%
Normalized name: LIDOCAINE 0.5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 0.5% (10 mL)
Study: 24534012
Drug: Dietary insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary insulin load
Study: 23751748
Drug: Diagnostic protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic protocol consisting of judgment possible site, determining probable etiology, checking and feedbacks on laboratory test in 12 hours, and reassessment and adjustment treatment in 48-72 hours.
Study: 9043839
Drug: Simvastatin (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (combined 20 mg and 40 mg)
Study: 3280388
Drug: Charcoal hemoperfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Charcoal hemoperfusion for 5 or 10 hours daily in trial A (75 patients with grade 3 encephalopathy)
Study: 3280388
Drug: Charcoal hemoperfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Charcoal hemoperfusion for 10 hours daily in trial B (62 patients with grade 4 encephalopathy)
Study: 3280388
Drug: Etiologic subgroups
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etiologic subgroups (acetaminophen, hepatitis A, hepatitis B, presumed non-A, non-B hepatitis, halothane or drug reaction)
Study: 30173448
Drug: Huanshao Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huanshao Capsules (HSC) at the dose of 3 capsules tid for 12 weeks
Study: 22474997
Drug: Wuziyanzong Pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuziyanzong Pills at 6 g bid for 12 weeks
Study: 25089280
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with partially hydrolyzed guar gum (PHGG) for 10 months
Study: 25089280
Drug: No maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maintenance therapy (Control group)
Study: 22681769
Drug: artemether-lumefantrine (AL),
Approvals — FDA: no, EMA: no, PMDA: no
Description: artemether-lumefantrine (AL), 3-day, twice daily oral administration
Study: 19104169
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion (0.075 microg x kg x h)
Study: 17879400
Drug: Combined intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous and oral antioxidants
Study: 17879400
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of antioxidants
Study: 11876696
Drug: Chewable CaCO3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewable CaCO3 tablets (750 mg, 1500 mg, 3000 mg)
Study: 11876696
Drug: Effervescent bicarbonate
Normalized name: potassium bicarbonate Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent bicarbonate solution
Study: 11876696
Drug: Swallowable CaCO3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowable CaCO3 tablets
Study: 2296985
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin A (200,000 IU)
Study: 153679
Drug: Clofezone (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofezone (1200 mg for the first week, 600 mg for the second week)
Study: 153679
Drug: Diclofenac (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (150 mg for the first week, 75 mg for the second week)
Study: 7223751
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of allopurinol tablets (300 mg)
Study: 7223751
Drug: Cocoa butter
Normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa butter suppositories (300 mg allopurinol)
Study: 7223751
Drug: PEG suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG suppositories (300 mg allopurinol)
Study: 31709115
Drug: Low-dose Edaravone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Edaravone Dexborneol (12.5 mg)
Study: 31709115
Drug: Medium-dose Edaravone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose Edaravone Dexborneol (37.5 mg)
Study: 31709115
Drug: High-dose Edaravone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Edaravone Dexborneol (62.5 mg)
Study: 31709115
Drug: Edaravone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone (30 mg) - Control group
Study: 28199364
Drug: Low‐Molecular‐Weight Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐Molecular‐Weight Heparin (LMWH) - dalteparin (Fragmin®) 5000 IE once daily
Study: 25720712
Drug: Strengthened antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strengthened antihypertensive (intravenous antihypertensive drugs controlled at 130‐140 mmHg for 24 h)
Study: 25720712
Drug: Normal antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal antihypertensive (intravenous antihypertensive drugs controlled at 160‐180 mmHg for 24 h)
Study: 25720712
Drug: Strengthened antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strengthened antihypertensive
Study: 25720712
Drug: Normal antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal antihypertensive
Study: 24088416
Drug: Fermented red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented red ginseng (FRG) capsules
Study: 22324379
Drug: KW-7158 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-7158 (oral administration)
Study: 12105831
Drug: Antibiotics (ciprofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (ciprofloxacin and metronidazole, both 500 mg twice daily) + budesonide (9 mg once daily)
Study: 12105831
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + budesonide (9 mg once daily)
Study: 12105831
Drug: Antibiotics (ciprofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (ciprofloxacin and metronidazole, both 500 mg twice daily)
Study: 7782014
Drug: Formalized follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formalized follow-up protocols (e.g. bone scintigraphy, chest X-ray, abdominal ultrasound, mammography, laboratory investigations)
Study: 113807
Drug: Amitriptyline (AMI)
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline (AMI) 150 mg/day for 6 weeks
Study: 23611977
Drug: Autologous UCB
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous UCB infusion, 1 year of daily oral vitamin D (2000 IU), and DHA (38 mg/kg) and intensive diabetes management
Study: 16952492
Drug: 6-drug cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-drug cocktail (flurbiprofen 50 mg, caffeine 100 mg, mephenytoin 100 mg, debrisoquin 10 mg, chlorzoxazone 250 mg, dapsone 100 mg)
Study: 16952492
Drug: 5-drug cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-drug cocktail (caffeine 100 mg, mephenytoin 100 mg, debrisoquin 10 mg, chlorzoxazone 250 mg, dapsone 100 mg)
Study: 16952492
Drug: flurbiprofen alone
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: flurbiprofen alone (50 mg)
Study: 15609591
Drug: Combined Acupuncture-Drug
Normalized name: antibiotics in combination with other drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Acupuncture-Drug Anesthesia (AA)
Study: 12366880
Drug: Intermittent targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent targeted therapy
Study: 1867917
Drug: Continuous maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous maintenance therapy
Study: 9468465
Drug: Antenatal thyrotropin-releasing
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal thyrotropin-releasing hormone (400 microg each at eight-hour intervals, four doses)
Study: 7876650
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine by jet injector
Study: 7876650
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine by needle
Study: 7876650
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine by needle
Study: 7876650
Drug: Both hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both hepatitis vaccines by needle in separate arms
Study: 7067925
Drug: Metronidazole 2
Normalized name: metronidazole 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 2 g single dose
Study: 389352
Drug: Metronidazole 400
Normalized name: metronidazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 400 mg twice daily for five days
Study: 30649593
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (100,000 IU single bolus followed by 4,000 IU daily for 16 weeks)
Study: 29512200
Drug: brodalumab 140
Normalized name: brodalumab 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: brodalumab 140 or 210 mg every 2 weeks (Q2W)
Study: 20932521
Drug: Cement augmentation
Normalized name: Cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cement augmentation technique (group A, 40 patients)
Study: 20932521
Drug: Cement augmentation
Normalized name: Cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cement augmentation technique (group A)
Study: 6401442
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine
Study: 7573998
Drug: Both intravenous
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intravenous and epidural clonidine
Study: 2015917
Drug: Breast conserving
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast conserving treatment